Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.050
-0.010 (-0.49%)
At close: Dec 5, 2025, 4:00 PM EST
2.040
-0.010 (-0.49%)
After-hours: Dec 5, 2025, 7:53 PM EST
Outlook Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Outlook Therapeutics stock have an average target of 5.25, with a low estimate of 1.00 and a high estimate of 9.00. The average target predicts an increase of 156.10% from the current stock price of 2.05.
Analyst Consensus: Buy
* Price targets were last updated on Sep 30, 2025.
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $1 | Hold | Reiterates | $1 | -51.22% | Sep 30, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $21 → $8 | Strong Buy | Maintains | $21 → $8 | +290.24% | Sep 22, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $1 | Strong Buy → Hold | Downgrades | $1 | -51.22% | Aug 29, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +46.34% | Aug 28, 2025 |
Financial Forecast
Revenue This Year
6.86M
Revenue Next Year
30.38M
from 6.86M
Increased by 342.80%
EPS This Year
-1.68
from -4.06
EPS Next Year
-0.99
from -1.68
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 13.2M | 63.9M | ||||
| Avg | 6.9M | 30.4M | ||||
| Low | 4.1M | 15.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 831.8% | ||||
| Avg | - | 342.8% | ||||
| Low | - | 127.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.56 | -0.29 | ||||
| Avg | -1.68 | -0.99 | ||||
| Low | -1.78 | -1.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.